Tags : Pear Therapeutics

Weekly Snapshot

PharmaShots Weekly Snapshot (Nov 16-20, 2020)

Eli Lilly and Incyte Receive FDA’s EUA for Baricitinib + Remdesivir to Treat Hospitalized Patients with COVID-19 Published: Nov 20,2020 | Tags: baricitinib, COVID-19, Eli Lilly, Emergency Use Authorization, FDA’s, Incyte, receives, Remdesivir Novartis Signs a License Agreement with Mesoblast to Develop and Commercialize Remestemcel-L for ARDS Published: Nov 20,2020 | Tags: Agreement, ARDS, Commercialize, […]Read More

Top 20

Top 20 Innovative Digital Therapeutics Companies of 2019

The recent decades have shown an accelerated development and evolution in the technology world, leading to unexpected growth in digital health companies. With the aid of health information technology, wearable devices, telehealth, telemedicine, and personalized medicine HCPs can make better insights for treatments and early diagnosis of life-threatening diseases Our team at PharmaShots has categorized […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (October 28 – November 01, 2019)

1. Medtronic Reports MHLW’s Shonin Approval and Launches Valiant Navion Thoracic Stent Graft System in Japan Published: Oct 31, 2019 | Tags: Medtronic, Reports, MHLW, Shonin Approval, Launches, Valiant Navion Thoracic Stent Graft System, Japan  2. Beam Therapeutics Signs Exclusive License Agreement with Prime Medicine for Prime Editing Technology Published: Oct 31, 2019 | Tags: Beam […]Read More


Pear Therapeutics Signs an Agreement with Ironwood to Assess Prescription

Shots: The companies collaborated to explore developing PDTs for the treatment of patients with selected indications within the gastrointestinal space The focus of the agreement is to merge Pear’s expertise in PDTs with Ironwood’s GI franchise and clinical expertise and to expand Pear’s portfolio outside the central nervous system The collaboration will provide an opportunity […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (October 14-18, 2019)

1. Johnson & Johnson Initiates Voluntarily Recall of a Single Lot of its Baby Powder in the US Published: Oct 18, 2019 | Tags: JnJ, Initiates, Voluntarily, Recall, Baby Powder, US 2. AbbVie’s Rinvoq (Upadacitinib) Receives CHMP Positive Opinion to Treat Moderate to Severe Active Rheumatoid Arthritis Published: Oct 18, 2019 | Tags: AbbVie, Rinvoq, Upadacitinib, Receives, […]Read More


Sandoz Terminates its Prescription Digital Therapies Agreement with Pear Therapeutics

Shots: Pear Therapeutics will solely be responsible for commercialization of its prescription digital therapeutics (PDTs), reSET and reSET-O, therapies to treat substance use disorder (SUD) and opioid use disorder (OUD) respectively In Apr’2018, the companies collaborated to develop and commercialize PDTs. The termination of prescription app deal is a part of Sandoz transformation and subsequent […]Read More